FDA Calendar, Unbiased Reporting on Emerging Biotech Sector Now Available at BioMedReports.com (Business Wire via Yahoo! Finance)
PITTSBURGH----BioMedReports.com, designed by and for investors and traders, is a full news portal offering unbiased bio stock reporting and analysis about emerging biotech companies, FDA and clinical trial calendars, and valuable industry and stock market information.

Mylan seeks Tarceva and Lunesta generic approvals (AP via Yahoo! Finance)
Generic drug maker Mylan Inc. said Thursday it is seeking approval for four drugs, including low-cost versions of the sleep aid Lunesta and cancer pill Tarceva, and is being sued by the makers of each product.

FDA Approves New Indication For Wyeth's TYGACIL (tigecycline) For The Treatment Of Adult Patients With Community ... (Medical News Today)
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) approved TYGACIL(R) (tigecycline), for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible strains of indicated pathogens.